Navigation Links
FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Date:9/14/2007

sal phase of their lives, the incidence of certain diseases, such as invasive breast cancer and osteoporosis, increases dramatically," said Steven Cummings, M.D., emeritus professor of medicine and epidemiology and biostatistics at the University of California San Francisco. "Therefore, it's important for postmenopausal women to be aware of these serious risks and have treatment choices to address them."

The FDA evaluated a data package that included multiple trials assessing three different populations of postmenopausal women:

-- The Study of Tamoxifen and Raloxifene (STAR) trial, sponsored by the National Cancer Institute (NCI) and coordinated by the National Surgical Adjuvant Breast and Bowel Project (NSABP), involved postmenopausal women at increased risk for invasive breast cancer. The observed incidence rates of invasive breast cancer were EVISTA 4.4 and tamoxifen 4.3, per 1000 women per year.

-- The Raloxifene Use for The Heart (RUTH) trial looked at postmenopausal women with known or at increased risk for coronary disease. The study demonstrated that EVISTA significantly reduced the risk of invasive breast cancer in postmenopausal women by 44 percent with an absolute risk reduction of 0.6 percent.

-- The Multiple Outcomes of Raloxifene Evaluation (MORE) and Continuing Outcomes Relevant to Evista (CORE) trials evaluated postmenopausal women with osteoporosis. Both four-year trials showed that EVISTA reduced the risk of invasive breast cancer in women by 71 percent with an absolute risk reduction of 1.1 percent, and 56 percent with an absolute risk reduction of 1.0 percent, respectively.

Important Safety Information About EVISTA(R)

EVISTA is not for everyone. If you are or still can become pregnant, are nursing, or have had blood clots that required a doctor's treatment, you cannot take EVISTA. An infrequent but serious side effect of EVISTA is blood clots in the veins - being immobile for a long time may add to the risk.'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. FDA approves IND on Lead Product M6G
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
5. Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, 2015 ... OFF HOLD -- FN Media Group LLC, PIV757417 ... Partnerships Focus on Developing Orphan Drug Products & ... is now OFF HOLD. Distribution time: 3 Aug ... development agreements between biotech companies, military surgical research ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
(Date:8/3/2015)... , ... August 03, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today welcomed the ... for review OPKO’s New Drug Application for a new treatment for chronic kidney ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... today that Joe Williams has joined its growing California employee benefits division. ... service model to his clients. Mr. Williams will be joining the newly integrated ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... A new study has dismissed any association between consumption of ... association between total calcium intake//, and consequent changes in body ... intake of calcium. ,More than 19,000 men between ... a 12-year period. All of the study participants consumed a ...
... health benefits. Now, teens, who want that dream weight, can ... obesity at bay, according to a new study. Researchers at ... combined yoga with breathing exercises certainly helped knock off the ... boys participated in a study. They were divided into two ...
... appear to have scaled up following the improvement in ... flu outbreak abated.// , ,According to an official ... been some improvement in the movement of these commodities ... in the last four days. Poultry consumption too has ...
... Information (CIHI) said that despite the government investing a ... of waiting time. // Glenda Yeates, president of the ... and high-priority procedures has increased dramatically. ,But ... much. Statistics show that the number of angioplasties and ...
... study claims that calcium intake was not associated with weight ... published in the American Journal of Clinical Nutrition. ... enrolled in the Health Professionals Follow-up Study were taken as ... between total calcium intake from diet and supplements and changes ...
... eastern Sarawak state of Malaysia is causing concern among Malaysian ... all schools in the area to prevent the disease from ... causes the disease, has so far affected more than a ... peninsular Malaysia, the health ministry will take a clear line ...
Cached Medicine News:
... The ESR-100 is an automated 100-position ESR ... 50 samples daily. The instrument accurately and ... in 1.2ml or 2.0ml ESR-Vacuum Tubes. Results ... Westergren Method) and are available in 30 ...
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... Qwik-Let® Premier is our top-of-the-line ... the attributes of the Qwik-Let® ... patented Lan-X feature. The Lan-X ... and protection in the removal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
Medicine Products: